三诺生物李心一：推动可穿戴医疗设备研究开发

Core Viewpoint - Sanofi Biotech has established itself as a leader in the diabetes management sector, focusing on innovative solutions and expanding its product offerings to enhance patient care and health outcomes [1][2]. Group 1: Company Overview - Sanofi Biotech is recognized as the "first stock" in China's blood glucose industry and ranks as the fourth largest blood glucose meter company globally [1]. - The company serves over 25 million users worldwide, with products and services available in 187 countries and regions [1]. - In China, more than 50% of individuals who self-monitor their blood glucose levels use Sanofi's products [1]. Group 2: Strategic Direction - The company is extending its focus into diabetes medical services, emphasizing a digital management model that integrates biosensing, IoT, smart healthcare, and lifestyle guidance [2]. - Sanofi aims to shift diabetes management from a disease-centered approach to a health-centered approach, as outlined in the National Health Commission's plan for diabetes prevention and treatment from 2024 to 2030 [2]. Group 3: Product Development - Continuous Glucose Monitoring (CGM) systems are identified as a critical area for strategic development, providing comprehensive and reliable blood glucose information [2]. - Sanofi has completed the development of its second-generation CGM product, which has been launched domestically and received EU CE-MDR certification for sales in EU-recognized countries [3]. - The company is integrating artificial intelligence into chronic disease management, with its SinoGPT technology already operational [3]. Group 4: Future Investments - A global R&D center is set to be established, with an anticipated investment of 500 million yuan, focusing on the biosensing industry chain [3]. - Future R&D efforts will include artificial pancreas and insulin pump technologies to provide comprehensive solutions for chronic disease management [3].